Author: Biocytogen Boston

7th Tumor Models for Immuno-Oncology Summit

December 27, 2022

Join us at the 7th Tumor Models for Immuno-Oncology Summit in San Francisco, CA from January 24 – 26, 2023! We will be presenting “Next-Generation Mouse Models to Evaluate Efficacy of Novel Antibody and Cell-Based Immunotherapies” at 10:15AM PST on Thursday, Jan. 26. Speaker Session: Thursday, Jan. 26, 10:15AM PST Speaker: Jenna Frame, Ph.D.  Manager, […]

Read More

Biocytogen BDL Team to Participate in the 41st Annual JPM Healthcare Conference, the Biotech Showcase and BIO Partnering at JPM

December 21, 2022

Biocytogen (HKEX: 02315) will attend the upcoming 41st J.P. Morgan (JPM) Healthcare Conference week, and participate in several satellite conferences, including the Biotech Showcase and BIO Partnering at JPM, which are all to be held in San Francisco from January 9-12, 2023. The team will also present in the BFC conference and ACCESS CHINA before […]

Read More

Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008

December 19, 2022

BEIJING, China, December 19, 2022 — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (bsAb). The IND application was completed by Biocytogen’s wholly owned subsidiary […]

Read More

Back to top